Iovance Biotherapeutics is trading 4.06% down at $8.62 after its sharp two-session rally; no new company-specific announcement explaining the August 21, 2026 decline was identified.
- Recent support came from record second-quarter revenue of approximately $99.3 million and strong Amtagvi demand.
- UBS raised its price target to $7 but maintained a Neutral rating.
- The decline remains an unclear pullback rather than a confirmed fundamental reversal.